Tuesday, October 13, 2026
ExploreSearch
Via News
MarketIndexes

NYSE FANG Over 29% Up In The Last 21 Sessions

NYSE FANG Over 29% Up In The Last 21 Sessions

(VIANEWS) - NYSE FANG (NYFANG) has been up by 29.49% for the last 21 sessions. At 10:10 EST on Thursday, 13 April, NYSE FANG (NYFANG) is $5,991.98.

Regarding NYSE FANG's yearly highs and lows, it's 1.44% up from its 52-week low and 0.28% down from its 52-week high.

News about

  • According to Zacks on Tuesday, 11 April, "Being a staple among cosmetic products for over a century, L'Oréal stock is up +26% this year to outpace the S&P 500 and the Cosmetics & Toiletries Market."
  • According to Zacks on Tuesday, 11 April, "The picture gets uglier When you compare TSN's 10.49% gross margin to that of the S&P 500 (48.73).", "For example, S&P 500 has shot higher by 56.7% over the past five years while Tyson is down 15.7%."
  • According to MarketWatch on Tuesday, 11 April, "CarMax's stock has rallied 8.2% year to date through Monday, while the S&P 500 has gained 7.0%."
  • According to MarketWatch on Tuesday, 11 April, "CarMax's stock has rallied 8.2% year to date through Monday, while the S&P 500 has gained 7.0%."

More news about NYSE FANG (NYFANG).

Categories

MarketIndexes

Tags

IndexWorld IndicesIndicesNYFANGNYSE FANGPrice UpINDICES Price UpIndex Now
ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,372 source documents archived
Query this data → isubstrate.com